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ABSTRACT 
Eric T. Wittbrodt: Outcomes Research Using Claims Databases: A Critical Review and Case Study 
(Under the Direction of William A. Sollecito, DrPH) 
 
     Outcomes research (OR) is an evolving and critical part of health sciences research due to its focus on 
the improvement of patient care in the practice setting.  Evidence included in OR spans all available 
clinical information, from data generated by randomized controlled trials to real-world clinical, 
economic, humanistic, patient-reported, and patient satisfaction data. Comparative effectiveness 
research (CER) is a branch of OR that compares the overall benefit or cost of two active interventions. 
The use of claims databases has emerged as a valid, rigorous, and efficient source of data for CER. Due 
to the inability to control for all confounders, techniques such as propensity score matching and quality 
checks are necessary to maintain data accuracy and validity. A case study comparing two oral 
medications used in the treatment of gout will be used to illustrate the techniques, advantages, and 
disadvantages of using claims databases in OR.  
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LIST OF ABBREVIATIONS AND TERMS 
ACO   accountable care organization 
adherence   the act of a patient following an agreed-upon medication regimen  
AHRQ   Agency for Healthcare Quality and Research 
AMCP   Academy of Managed Care Pharmacy 
CDC   Centers for Disease Control and Prevention 
CER   comparative effectiveness research, the process of comparing in the   
   aggregate the overall benefit or cost of two active interventions   
   (typically pharmaceuticals or medical devices); evidence would include   
   randomized controlled trials (RCTs), economic analyses, observational studies,  
   registries, patient-reported outcomes (PROs), and others 
 
CKD   chronic kidney disease 
claims databases existing information that has been captured and stored in electronic   
   form for the primary purpose of processing payment claims for    
   healthcare services rendered 
 
CMS   Center for Medicare and Medicaid Services 
confounder  a variable inherent in a population being studied that contributes to random  
   error and obscures the effect of the intervention being tested on the outcome  
   of interest 
 
CONSORT  CONsolidated Standards Of Reporting Trials 
CPT   Current Procedural Terminology 
DACON   daily consumption (of medication) 
DHHS   Department of Health and Human Services 
EBM   evidence-based medicine 
effectiveness  impact of an intervention on a variable of interest that is demonstrated   
   in routine clinical practice or a “real world” setting 
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efficacy   impact of an intervention on a variable of interest in a highly restricted   
   and limited fashion for a discrete span of time; most closely associated   
   with data generated by randomized controlled trials (RCTs) 
 
EHR   electronic health record 
ESRD   end stage renal disease 
expenditures  financial resources allocated for the payment of a good or service 
FBX   febuxostat, an oral drug approved for treating hyperuricemia in patients with  
   gout 
 
FDA   Food and Drug Administration 
FY   fiscal year 
GE   General Electric Healthcare database 
gout   a form of painful joint inflammation caused by the deposition of uric acid  
   crystals in the lubricating fluid of the joint space 
 
HCPCS   Healthcare Common Procedure Coding System 
health outcome  the quality of patient care based on the result rather than the input 
 
HIPAA   Health Insurance Portability and Accountability Act (of 1996) 
hyperuricemia  elevation in serum acid concentration beyond the normal range 
ICD-9-CM  International Classification of Diseases, 9th Revision, Clinical    
   Modification 
 
IDN   Integrated (Healthcare) Delivery Network 
IOM   Institute of Medicine 
ISPOR   International Society for Pharmacoeconomics and Outcomes Research 
MDD   major depressive disorder 
MPR   medication possession ratio 
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Meaningful Use  the clause of the Patient Protection and Affordable Care Act (PPACA) that  
   provides CMS-based incentives and guidance for health care providers and  
   facilities to promote the use of electronic health records (EHR) 
 
NDC   national drug code 
NIH   National Institutes of Health  
OR   outcomes research, the study of the end result of health services that   
   takes patients’ experiences, preferences, and values into account and   
   is intended to provide scientific evidence for the purpose of shaping decisions  
   made by all who participate in health care 
 
PCORI   Patient-Centered Outcomes Research Institute 
pharmacoeconomics the subset of health economics that focuses on the cost of    
   pharmacotheraepeutic interventions and the services that support them 
 
PHI   protected health information 
PPACA   Patient Protection and Affordable Care Act (of 2010) 
PRO   patient-reported outcome 
propensity score a nonparametric method of patient matching for the purpose of mitigation of  
   random error in claims database studies in which a probability of receiving a  
   given intervention is assigned to each patient; the number ranges from 0 to 1  
   and is derived from all measured covariates 
 
PV   pharmacovigilance, post-marketing research in which the ongoing   
   surveillance of real-world information has a specific emphasis on drug   
   safety 
 
QIO   quality improvement organization 
quality   the benefit of an intervention or system that is directly measurable with  
   discrete and validated instruments and can be repeatedly assessed to gauge  
   improvement 
 
RCT   randomized controlled trial 
real-world  routine clinical practice in an uncontrolled environment in a diverse   
   patient group 
 
9 
 
STROBE   STrengthening the Reporting of OBservational studies in Epidemiology 
triple aim  improved quality, reduced cost, and improved patient experience of   
   health care encounters, a primary driver of value-based health care 
 
ULT   urate-lowering (drug) therapy 
US   United States 
value   high quality care that produces the best outcomes in a wholly cost-  
   conscious manner; calculated as the clinical benefit of an intervention divided  
   by its total cost 
 
value-based care a network of hospitals and providers that are united by a shared   
   responsibility for improved patient outcomes and enhanced fiscal   
   accountability, examples include accountable care organizations (ACOs)   
   and integrated healthcare delivery networks (IDNs) 
 
XOI    xanthine oxidase inhibitor 
WHO   World Health Organization 
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Chapter 1: OUTCOMES RESEARCH 
  Introduction     
      Health sciences research, especially that which is conducted by the pharmaceutical, diagnostic, 
and medical device industries, may take many forms, but all share a common purpose: to determine 
the intervention (typically a drug, device, procedure, diagnostic tool, or delivery system) that yields 
the best possible health outcome for individual patients or for a specific population of affected 
individuals. Traditional research methods include randomized controlled trials (RCT) in which an 
active intervention is directly compared with a placebo, sham, or active control in two or more 
groups of subjects, usually in parallel fashion. The RCT is usually prospective in nature, and is 
designed to occur in controlled environments such that the impact of potential interfering factors, 
or confounding variables, on the outcome of interest are minimized. Due to regulatory requirements 
and their generally accepted scientific rigor, RCTs have continued to occupy a pivotal role in health 
sciences research. In addition, the adoption of evidence-based medicine (EBM) is rooted in the 
development of care protocols and guidelines that rely on information gleaned from the findings of 
RCTs often coupled with expert opinion. But, there remains an unmet need for data generated from 
the use of interventions in less well-controlled environments. Such “real-world” studies focus on the 
evaluation of health outcomes in the patient care system.  For example, the lack of robust and long-
term safety data in many RCTs has prompted the US Food and Drug Administration (FDA) to 
mandate pre- and post-marketing safety studies with specific types of interventions, such as oral 
antidiabetic drugs, or in selected groups of patients, such as individuals with a high risk of coronary 
vascular events. The science of pharmacovigilance (PV), as will be discussed, is another example of 
post-marketing research in which the ongoing surveillance of real-world information has a specific 
emphasis on drug safety. This is also an area where public health and individual health care 
intersect, focusing on the prevention of adverse events and other patient harms, occupying a 
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broader scope than traditional RCTs, and often including large populations or communities followed 
over long periods of time.   
      The concept of “outcomes research” (OR) in the health sciences is fairly recent, and was initially 
commonly discussed in the 1990s. Prior to that, research methods documented early evidence that 
aseptic technique reduced postsurgical mortality and the impact of battlefield casualty treatment on 
outcomes in soldiers during the Crimean War and World Wars I and II. In a formative paper by 
Donabedian (1966), outcomes in a medical context were defined as the “measures of the quality of 
care.” The limitations of outcomes assessment in this same paper included the caveat that 
outcomes may not always be relevant versus the processes employed to achieve them, and that 
many factors that influence outcomes must be taken into account. Ellwood, in the 1988 Shattuck 
lecture to the Massachusetts Medical Society, was likely the first individual to publicly mention the 
phrase health outcomes in the context of measuring the quality of patient care based on results 
rather than inputs. He also envisioned a nationwide repository of information where patients and 
providers could compare the quality and cost of interventions and delivery systems. While these 
observations were prescient, an entire decade elapsed before the systematic investigation of the 
impact of interventions on health outcomes took shape. The phrase “outcomes research” is believed 
by many to have been coined in print by Clancy and Eisenberg (1998) and was defined by these 
authors as “the study of the end results of health services that takes patients’ experiences, 
preferences, and values into account…intended to provide scientific evidence relating to decisions 
made by all who participate in health care” (p. 245). In other words, the drivers of OR are not 
derived solely from an intervention or provider, but rather are also dependent upon the attributes 
and needs of the end user, the patient. In 2013, the definition has expanded to include any research 
activities that seek to better explain, define, or confirm the clinical application of an intervention, 
especially in comparison with other interventions (including no intervention) in the presence of the 
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patient-related aspects described above. Also, the set of factors that affect patient outcomes has 
grown to encompass those that relate to the patient’s provider, payer, health care delivery system, 
geographic location, and social support. This ever-growing list is consistent with the vast expansion 
of the types of data that are available for a patient’s health care encounters that will be discussed 
later in this paper. In addition, all of these items comport with the well-described social 
determinants of health, including individual behaviors and characteristics (demographics, genetics, 
socioeconomic status, educational level, and occupation), interpersonal or social interactions, 
community conditions, and political or access factors that impact outcomes (CDC, 2011). The 
discipline of OR, then, helps cast a wider view of the impact of interventions beyond efficacy, that 
effect on a variable of interest in a highly restricted and limited fashion for a discrete span of time 
that is most closely associated with data generated by RCTs. This is contrasted with effectiveness, in 
which this same effect is demonstrated in a larger and more diverse cross-section of patients in 
routine clinical practice. Interest in identifying the true clinical merits of two or more interventions 
in a population has created innovative subtypes of OR including comparative effectiveness research 
(CER). This paper will address the growing infrastructure to support CER in the US and also some of 
the misperceptions around its utility and that of OR in general. Some of the primary applications of 
OR in the realm of public health also will be discussed.  Due to the dire need for better evidence to 
build upon RCTs, the increased availability of vast amounts of health-related data often in electronic 
form, and enhanced techniques that facilitate rapid and efficient analysis and interpretation of such 
data, the field of OR is more timely and relevant than ever. Novel data sources, such as secondary 
databases, offer great versatility to OR investigators. As a result, decision-makers are better 
equipped, and patients and providers are more empowered. Striving for the “triple aim” of 
increased quality (with a favorable risk-benefit profile), reduced cost, and improving the patient 
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experience is now the dominant trend in US health care (Berwick, 2008). Outcomes research is an 
important tool for the fulfillment of this aim. 
 
1. Goals 
The goals of this paper are as follows:  
a. Explain the concept and branch of science that is OR through a description of its 
attributes, purpose, and relevance to both individual health care practice and public 
health. 
b. Describe comparative effectiveness research (CER) and distinguish it from other types 
of OR, especially in the context of recently implemented health care legislation, 
including the Patient Protection and Affordable Care Act (PPACA). 
c. Explain the methods and data sources used in OR with a focus on secondary data 
sources, and administrative claims databases in particular. 
d. Illustrate the applications, advantages, and drawbacks of claims database research 
when investigating an OR question through an example case study design and 
available data sources comparing two different drug therapies for gout. 
 
2. The Role of Outcomes Research in Health Care  
 
 2.1 Relevance to patient care and public health 
     RCTs are the gold standard for the evaluation of efficacy, but stakeholders who require insight into 
the effectiveness of treatments in a larger and more diverse group of patients can no longer rely solely 
on RCTs for guidance. The availability of everyday clinical experience with an intervention is lacking in a 
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system fraught with variable prescribing patterns and medically complex patients (often from 
demographic groups vastly underrepresented in RCTs) (Schneeweis & Avorn, 2005) with inconsistent 
health care coverage and intermittent access to treatment. Such information is essential for well-
informed decisions about care. The decisions may affect individual patients, e.g., treatment protocols 
and prescription coverage, or populations, e.g., access to care and reimbursement. Conducting carefully 
designed and thoughtfully executed retrospective OR studies using secondary claims databases is one 
common approach to augment this body of knowledge. Since OR is a relatively new field some experts 
have expressed disagreements amongst themselves about its scope, relevance, and purpose. For 
example, Krumholz (2008) attempted to debunk common “myths” about OR in a recent editorial. He 
suggested that this type of research is not monolithic in its approach to scientific inquiry and therefore is 
not an individual field of study, rather it is multidisciplinary by design. The applied health sciences are 
traditionally at its core, but also techniques from the fields of statistics, epidemiology, and the social and 
behavioral sciences (among others) comprise essential components of outcomes investigations. 
Krumholz also posited that OR must be aligned with existing health care problems in the presence of a 
feedback loop that contributes to the impetus and blueprint for subsequent investigations. The 
interconnectedness, dynamism, and progressively building characteristics inherent in OR explain its 
growing relevance and applicability to vexing and contemporary health care issues.  
     In terms of public health, OR has been instrumental in defining areas of need for intervention 
programs in multiple disease states such as heart failure and myocardial infarction (Roger, 2011). Such 
conditions contribute tremendously to the clinical and economic burden of the patients affected and the 
health care system in which their diseases are managed. Identification of needs in at-risk or vulnerable 
populations based on measured health disparities is often rooted in geography, socioeconomic status, 
and race, is an important function of OR. The population health aspects of this type of approach 
illustrate the synergistic relationship between epidemiology, health education, and OR principles. 
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Another example of the intersection of OR and public health is in the aforementioned science of 
pharmacovigilance (PV). The numerous withdrawals of drugs from the US market due to excessive safety 
signals prompted a growing need for the continuous monitoring of both anticipated and unforeseen 
adverse events in the population exposed to an intervention of interest. The World Health Organization 
(WHO) included these monitoring activities in its definition of PV, and extended it to include the 
interpretation of drug safety data in an effort to develop programs to prevent further harm (WHO, 
2013). The FDA also uses PV information to determine if a prospective trial is needed to assess the long-
term safety of a product in clinical use. The use of OR techniques in PV activities is essential, because 
both depend on the evaluation of routinely collected data in the everyday setting. 
 
     2.2 Evolution of pharmacoeconomic research to outcomes research 
     The branch of study called health economics is dedicated to the evaluation of the financial burden or 
cost of health care services. Pharmacoeconomics is the subset of health economics that focuses on the 
cost of pharmacotheraepeutic interventions and the services that support them (Bootman et al., 1996). 
The historical function of pharmacoeconomic data is to support informed decisions about the allocation 
of resources for various drug therapies. Such data are not intended to be considered in isolation, but 
rather in conjunction with clinical evidence for efficacy, safety, and other noneconomic factors. The 
budgets for the various components of a health care system or payer, e.g., hospitalization, ambulatory 
care, pharmacy, radiology, mental health services, and clinical laboratory services, have traditionally 
occupied distinct and separate compartments or “silos.” The department that is held accountable for its 
own budget separate from the whole has not usually been concerned with the overall economic impact 
of an intervention to the system. This mindset has undergone a significant shift as the quality of care 
delivered by the entire system begins to drive reimbursement for health care services. Thus, decision-
makers who focus solely on cost of an intervention, especially in the current era of high budgetary 
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restraint, demonstrate short-sightedness, because the cost of care extends far beyond this one item. 
One must consider all of the downstream cost implications of an intervention in a holistic fashion. 
Consider an example where the cost of drug A may be twice that of drug B, but the collective evidence 
demonstrates three fewer hospitalizations for disease recurrence with drug B. The cost of each 
hospitalization is determined to far exceed the difference in cost between the therapies. In this 
example, neglecting to consider the impact of an intervention on the total cost of care may positively 
affect the drug budget (due to selection of the less expensive agent), but have the reverse effect on the 
health care system overall. To be wholly cost-conscious, but also deliver high quality care that produces 
the best outcomes, is known as the pursuit of value. More specifically, value is defined as the clinical 
benefit of an intervention divided by its total cost (Chassin & Galvin, 1998). Clinical benefit is evidenced 
by statistically or meaningfully significant improvement in the health status of a patient after a specific 
intervention. The positive change in health status is denoted by a measured variable or variables of 
interest that ultimately is expected to yield better outcomes for the individual. The variable can be an 
outcome itself, such as disease-free survival, or can be a surrogate outcome, such as a decrease in blood 
cholesterol concentration that is correlated with a significantly decreased risk of heart disease.  
     Value is not identical to quality, because the latter is the benefit that is directly measurable with 
discrete and validated instruments and can be repeatedly assessed to gauge improvement. Another 
definition of quality involves the patient experience. That is, the twin facets of efficient delivery of care 
and effective management of disease are inextricably linked, and the issue of access to quality care 
becomes paramount in this definition (Campbell, 2000). From the increasing use of these terms (value 
and quality), one may conclude that over time, the evolution away from a strictly economic focus has 
occurred in response to often valid criticism that overarching financial concerns needlessly led to worse 
patient outcomes in many cases. In response to this, the health care environment is rapidly taking a 
more comprehensive approach to the economic burden of illness to include not only the cost of medical 
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care (known as direct costs), but also the costs of lost work productivity and time spent in the health 
care system, and the cost of shortened lifespan and reduced quality of life (known as indirect costs).  
     Moreover, the demonstration of better outcomes for the health care dollars spent is now being 
demanded by multiple sectors, including payers, employers, and health care systems. In fact, much of 
the impetus for the PPACA, aside from the vast numbers of uninsured Americans, is the fact that the US 
health care expenditure per capita on health care was in excess of $7,500 US in 2008 (Kaiser Family 
Foundation, 2008). This amount is more than for any other nation, yet overall health outcomes are far 
from desired (the US is ranked 36th for life expectancy among the world’s nations) (WHOSIS, 2009). 
Although multiple factors may be implicated in suppressing life expectancy at birth, it is a disturbing 
trend that continues to worsen despite the economic largesse dedicated to US health care. Growing 
acknowledgement of this gap in cost and quality necessitated the transformation of 
pharmacoeconomics from a prominent decision-making tool to become but one facet of a multipronged 
approach that also includes consideration of clinical, humanistic, and, now, patient satisfaction data. The 
sum total of these approaches can be colloquially thought of as OR.   
 
     2.3  Comparative effectiveness research (CER) and the PCORI initiative 
     Strictly isolating the assessment of patient benefit to clinical efficacy in a controlled setting such as an 
RCT perhaps coupled with cost minimization is an approach now being questioned by many sectors of 
the health care system. This is due to the realization that the quality of care in ordinary care settings and 
the patient experience represent glaring omissions from this equation. Adoption of effectiveness as a 
critical facet of evaluating new interventions reflected a sea change in thinking about this task. A new 
phrase, comparative effectiveness research (CER), was invoked by the Institute of Medicine (IOM, 2007) 
and others to describe the process comparing in the aggregate the overall benefit or cost of two active 
interventions (typically pharmaceuticals or medical devices). The body of available evidence used in CER 
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evaluations includes RCTs, economic analyses, observational studies, registries, patient-reported 
outcomes (PROs), and others. This list continues to expand as the understanding of scientific methods in 
CER improves and different types of data become more readily available in electronic form. For 
example, the impact of disease management programs within a health system can be captured if a 
connection exists for electronic health records (EHR) between the inpatient and outpatient facilities, as 
in many systems. Documentation of specific or overall health aspects of a patient’s care outcomes and 
experience with health care delivery can be recorded using PRO tools usually in web-based and other 
electronic formats. This information can be linked to the EHR for a particular patient and incorporated 
into a CER analysis. The PROMIS tool developed by the National Institutes of Health (NIH) is one example 
of a PRO (NIH, 2013). The highest utility of PROs occurs when patients are engaged in their development 
and testing before implementation; this helps achieve one of the hallmarks if CER: increased patient-
centeredness.  
     The enactment of the PPACA in 2010 ushered in many stepwise changes to the US health care 
system, particularly in the areas of health care financing, reimbursement, and delivery. However, one 
feature of the PPACA not widely appreciated is the creation of the Patient-Centered Outcomes Research 
Institute (PCORI), a nonprofit corporation whose defining purpose is to identify knowledge inadequacies 
in health care in an effort to systematically foster the design and execution of evidentiary analyses 
(Clancy & Collins, 2010). Although PCORI is a non-governmental entity, its financial support is provided 
by the general fund appropriated by Congress as a function of the PPACA and also by an annual fee of $2 
per person for all individuals covered by Medicare and commercial (including self-insured) insurance 
plans. This support will continue through the end of FY 2019 (PCORI, 2013). The ultimate goal of PCORI is 
to better equip health care decision-makers with more robust and well-considered information based on 
the totality of clinical, economic, humanistic, and patient-centered data that are available. If significant 
gaps exist in these data, then PCORI is charged with the facilitation of additional research to bridge such 
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knowledge deficits. PCORI is closely aligned with the Agency for Health Care Quality and Research 
(AHRQ) and the NIH both of which will assist in the rapid dissemination of research results from 
investigators who are supported with grants awarded by PCORI. The development of the research plan 
for PCORI (called the National Priorities and Research Agenda) occurs through assessment of US public 
health needs, disease state prevalence and burden, and solicitation of expert opinion and public 
comment, including those from patients and consumers. The public source of funding for PCORI 
contributes to its mission to address the most pressing CER-related issues that affect a large number of 
US citizens. The current agenda consists of five broad categories: 
1.  Prevention, diagnosis, and treatment options; 
2. Healthcare system improvement; 
3.  Communication of research; 
4.  Health disparities; and 
5.  Fostering patient-centered OR and methods innovation (PCORI, 2013).  
To date, PCORI has awarded 71 research grants totaling $114 million to investigators in 35 states and 
the District of Columbia. In sum, the establishment of PCORI and the financial investment in patient-
centered OR represents an important juncture in US health care, because it is redefining the types of 
projects that are relevant to advances in the field. More importantly, redirection of the focus to the 
recipient of care, the patient, is moving to the forefront of PCORI-sponsored research which will help set 
the tone for much of health-related research in the future. This is a major departure from the status quo 
of health care decision-making, because the expanded breadth of research data emanating from PCORI 
and other purveyors of CER adds a much-needed dimension to the evidence-based process. In this 
manner, PCORI has clearly defined and resourced the development, validation, and promotion of PROs 
that extends far beyond what had been done before. For example, the creation of PROs in major 
depressive disorder (MDD) reflects a patient-centered approach to assessment of the effectiveness of 
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antidepressant medications, and is a useful supplement to traditional clinician-based rating scales for 
MDD. Other conditions which lack objective clinical endpoints, such as irritable bowel syndrome and 
chronic pain syndrome, also are amenable to research that includes tools used in CER. 
 
      2.4. Design, Data Sources, and Methods Considerations in Outcomes Research  
 
 2.4.1. Advantages of Claims Databases      
     One increasingly emergent trend in OR is the evaluation of existing information that has been 
captured and stored for the primary purpose of processing payment claims for health care services 
rendered. The employment of these secondary or administrative databases is a distinctly useful method. 
Many of the benefits of these databases, such as greater efficiency, lower expense, and reduction of 
bias have been described previously (Hall et al., 2011) and often outweigh their limitations, including 
incomplete or missing data and a lack of integration of different types of claims data (medical versus 
mental health versus prescription drug claims). This positive balance of attributes affords investigators a 
tool with great versatility and convenience. The lack of head-to-head active treatment comparison trials, 
especially with interventions past their patent expiration and many newer agents, can be addressed by 
evaluating multiple clinical and economic effects of interventions in a real-world environment using 
database studies. Evolving research design and analysis techniques for claims databases and the 
minimization of bias coupled with the rapid availability of results collected from patient encounters in a 
realistic setting have all combined to increase its popularity and acceptance in the scientific community. 
The “Meaningful Use” clause of the PPACA provides CMS-based incentives and guidance for health care 
providers and facilities to promote the use of electronic health records (EHR) (DHHS, 2013). This 
initiative builds upon the existing infrastructure of continuous quality improvement in Medicare, and the 
initiation of the Quality Improvement Organization (QIO) program, in 2002. The QIO program 
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coordinates the collection and housing of health care data for Medicare patients across the country in 
an effort to improve care. The data are collated and analyzed by the QIO and reported back to the 
provider with a focus on improving the delivery and outcomes of health care (Schenck, 2013). As such, 
the QIO program provides an example of how claims databases have been successfully used to answer 
relevant research questions and drive the improvement of care. Multiple QIOs endeavor in a 
collaborative manner to standardize procedures for data sharing and analysis. This approach has been 
demonstrated to be a valid means of generating evidence targeted at improving quality in patient care 
systems. As health care data become more complete in electronic form and disparate sources of 
information can be connected for an individual patient (also known as integration), the cost- and time-
intensive nature of this type of research will become more attenuated. In turn, the accessibility of more 
comprehensive datasets to a greater number of investigators will drive a demand for knowledge of the 
best practices for the execution and interpretation of OR using these claims databases.  
     Scientific and professional associations such as the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) (Motheral et al, 2003) and the Academy of Managed Care Pharmacy 
(AMCP) have developed and promulgated guidance documents for researchers interested in conducting 
analyses of claims databases. Commonly used and validated study designs from the field of 
epidemiology are used in claims database research and include retrospective cohort, prospective cohort, 
cross-sectional, case-control, and case-crossover (Aschengrau & Seage, 2008). The retrospective cohort 
design is especially attractive for this type of analysis, because it relies upon existing data and can be 
carried out relatively quickly and inexpensively.  Also, databases can be effectively “de-identified,” that 
is, devoid of any personal information that can be traced back to an individual, thereby satisfying 
institutional policies and good research practices for safeguarding the privacy of protected health 
information (PHI) as stipulated in the Health Insurance Portability and Accountability Act of 1996 
(HIPAA). Specifically, in 2013 the US Department of Health and Human Services released additional 
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guidance regarding the protection of PHI in the so-called Final Rule which enlarged the scope of HIPAA 
protections beyond the “covered entities” in the original law to include any firm that “creates, receives, 
maintains, or transmits PHI.” (GPO, 2013). Entities that conduct research with or provide access to PHI 
within databases are clearly covered under this rule, and it is incumbent upon such groups to develop, 
implement, and test systems to protect identifiable PHI. The creation of mobile applications where 
access to such information is readily available to patients, providers, and third parties has outpaced 
regulations to address potential security breaches (Wang, 2013). This is a pivotal issue in health services 
research, particularly using claims databases, that requires additional guidance. 
    The robustness of a data sample can be enhanced by including information from multiple sources 
pooled into a single database, and most large national health insurance payers, for example, offer the 
ability to sufficiently power a comparison to detect outcome differences between two or more 
interventions even in a patient population narrowly defined by specific characteristics, e.g., 
demographics and co-morbid conditions. Other proprietary databases, such as those owned by GE 
Healthcare and Truven, contain data from multiple payers, including the Center for Medicare and 
Medicaid Services (CMS), in order to capture both private (commercial) and public (government) payer 
data. This mix of healthcare financing mechanisms is quite desirable because it reflects a representative 
cross-section of US patients, and is likely to include data from across the spectrum of age and income. 
This fulfills one major advantage over RCTs which is the inclusion of a diverse sample of individuals with 
varied access to health care and myriad disease histories. Large databases also offer researchers 
sufficient sample sizes to evaluate rare diseases for which prospective RCTs are unfeasible due to the 
lengthy study period necessary for such investigations. 
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 2.4.2. Disadvantages of Claims Databases 
     Several limitations of claims databases must be acknowledged (van Walraven & Austin, 2012). The 
overriding concern arises from the immutable fact that these repositories exist for the primary function 
of the collection, adjudication, and storage of insurance claims. Use of this information for research 
purposes is secondary in nature, and much of the controversy around database research is linked to this 
fundamental problem. This realization has prompted a number of enhancements to claims databases in 
an attempt to provide a better platform for investigational work. For example, the integration of 
medical and pharmacy claims data, and, in turn, further coupling with patient-specific EHR can greatly 
streamline the research process. The risk of bias by unmeasured confounders is inherent in database 
research; this can be minimized by careful identification of the comparison groups so that they are well-
matched by potential confounding characteristics. If only commercially insured patients are included, for 
instance, then selection bias based on access to health care and income may be present. This type of 
bias may not be avoidable if the data are limited as such; however, this fact must be acknowledged as a 
flaw by the investigators. The dataset can be enriched with patients insured by Medicaid, the Veterans 
Administration, or Medicare if a more economically diverse sample is desired. Continuous enrollment 
for a specified period of time, such as one year, to qualify as an eligible patient for inclusion into a 
database study, overcomes some of the concern about intermittent coverage. Such a requirement is 
recommended, because the annual turnover or “churn” of managed care enrollees in a single plan has 
been reported to be as high as 40% (Short, 2003). However, the assertion of a “healthy patient bias,” a 
specific type of selection bias, has been implicated in some commercial insurance claims databases, e.g., 
United Health Care, because long-term privately insured patients have better access to care and tend to 
seek medical attention earlier, have fewer uncontrolled chronic conditions, and engage in healthier 
practices overall. As evidenced by the health care reform debate, uninsured lower-income Americans 
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usually delay addressing chronic conditions and seek emergent treatment only after disease severity has 
become untenable.  
     Access to a rich source of data often creates a temptation for investigators to “mine” the information 
and search for significant associations ad libitum. This is a common technique in market research but is 
unacceptable when deriving conclusions which are applied to patient care and public health decisions 
that can profoundly impact the lives of real people. However, data mining is often useful in exploratory 
studies in which the principal thrust is to generate hypotheses or questions to drive future research 
(Berger, 2009). In any event, adherence to scientific standards of hypothesis-testing database research 
requires the development of an analysis plan a priori that is followed through to completion after the 
data are collected. In this manner, convenient and post hoc analyses are strongly discouraged in that 
“fishing” for significant associations can be justly alleged. This plan is transparently communicated to 
reviewers of the protocol (for funding and patient protection) and to the peer community in the study 
report and any publications that result.  
     Other analytic considerations are worth mentioning. Since retrospective database analyses are not 
randomized and unmeasured confounding variables are impossible to completely eliminate (residual 
confounding), especially in real-world settings, investigators have utilized some techniques to mitigate 
random error. Propensity score matching is a nonparametric and commonly used method for this 
purpose in which a probability of receiving a given intervention is assigned to each patient; the number 
ranges from 0 to 1 and is derived from all measured covariates (Cox, 2009). Patients with identical or 
nearly identical propensity scores who receive different treatments are then matched for comparison. In 
other words, propensity score matching controls for undetected confounding baseline characteristics 
inherent in the data (Rubin, 1997). This is a more sophisticated and thorough method of cohort 
matching than traditional procedures that compare similar patients based on individual features such as 
age, sex, co-morbidity, or race/ethnicity.   
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 2.4.3. Other Considerations  
     The specific classification and identification of health care encounters by diagnosis and intervention 
(procedure, drug, or device) is a universal method of capturing a paid claim for health services. 
Diagnostic codes, e.g., the International Classification of Disease – Ninth Revision, Clinical Modification 
(ICD-9-CM) (CDC, 2013) and procedure codes, e.g., Current Procedural Terminology (CPT) (AMA, 2013) 
are well-accepted and commonly used data points in retrospective claims analyses. These coding 
systems along with the National Drug Code (NDC) (FDA, 2013) have been harmonized across the US 
health care system to facilitate consistency between care providers, payers, and systems. The 
availability of this information is highly amenable to multiple types of observational research. However, 
the congruence between a patient’s diagnostic code in the claims record and the clinical information 
found in the medical record (EHR) at the point of care (the patient’s chart) may be legitimately brought 
into question (Jollis et al., 1993). Therefore, the internal validity of the data collection process can be 
tested by comparing the two. For example, the set of ICD-9-CM codes assigned to the five stages of 
chronic kidney disease may be validated by taking a sample of patients with linked records (between 
claims and EHR) and verifying that the clinical measures of kidney function, such as serum creatinine or 
estimated glomerular filtration rate (eGFR) corroborate the former. In this manner, a vital quality 
control mechanism is fulfilled. Other routinely performed “quality checks” are necessary to determine 
the usefulness of the data (Johnson et al, 2009). For example, missing values are commonplace, 
especially among prescription claims records (Lauffenberger et al., 2013), and methods such as 
imputation or censoring of missing data must be transparently reported. Also, duplicate values and 
changes in disease coding and insurance coverage may compromise data validity.  
      Issues relevant to reporting the results of retrospective database research have been described. Due 
to the large sample sizes of patients included in these analyses, statistically significant but numerically 
small between-group differences may be over-interpreted. For example, consider a database analysis of 
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100,000 patients with Type 2 diabetes that is powered to detect differences in blood glucose 
concentrations of at least 1 mg/dL between two different treatments. The clinical importance of this 
small change in the measured endpoint is dubious where the threshold for significance may even be 
within the measurement error of the test (which may be as high as 10%), such as a laboratory value or a 
physiologic measurement like heart rate or blood pressure. While the risk of finding a significant 
difference between groups when none truly exists (known as a Type I error) may be very small (<5%, 
thereby satisfying statistical norms), the definition of a detectable difference needs to be rooted in 
practice-based reality. This criterion becomes more germane when the results of a retrospective 
database analysis conflict with previously conducted RCTs. The investigators of the former are then 
obligated to discuss reasons for this discordance and provide specific recommendations for 
interpretation of the data. Attempts to codify the proper description of OR results have recently 
occurred. The European Science Foundation convened an expert panel of researchers who developed 
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines that 
were published in 2007 (von Elm, 2007). Modeled on the CONSORT guidelines for the reporting of RCT 
results (Schulz, 2010), STROBE supplied a checklist of 22 items for investigators to consider as “essential 
for good reporting of observational studies.” The domains include the title and abstract, introduction, 
methods, results, discussion, and funding information. Of note, the key results with objectives fulfilled, 
limitations, interpretation, and generalizability of the study are denoted as core components of the 
discussion section, arguably the most revealing information in a research report. The underlying 
assumption of STROBE is that observational investigators are availed with ever increasing amounts of 
data from large numbers of patients, and it is incumbent upon this community to proceed with the same 
rigor and transparency as RCT investigators. Due to these enhancements in the conduct and reporting of 
OR studies, greater weight is being placed on the evidence that is generated. Notwithstanding the 
limitations of OR studies enumerated earlier in this paper, more credence than ever is placed in 
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observational study results, and the gravity of decisions made on their bases increases. Thus, it is 
imperative that the scientific, health care, and public health arenas must have the ability to attach the 
same reasonable certitude to the findings of observational studies as they do to RCTs.  
     What follows is an example of an OR study that employs many of the techniques described above to 
assess the overall health economic impact of two pharmacotherapeutic interventions for hyperuricemia 
in gout patients.  
 
Chapter 2. Case Study: A Comparative Evaluation of the Health Economic Outcomes of Febuxostat 
and Allopurinol in Gout Patients with Chronic Kidney Disease 
 
1. Disease State Background: Gout 
     Gout is a form of arthritis (joint inflammation) whereupon supersaturation of uric acid leads to crystal 
deposition in the lubricating fluid of the joint space (synovial fluid). This in turn activates the recruitment 
of specific types of white cells to the site, and the release of chemicals from these cells produces a 
localized, but intensely painful, inflammatory response (Schmerling, 2012).  
     The management of a gouty attack (also known as acute gout) involves mitigation of the 
inflammatory response with short-term drug therapy. After the flare resolves, with or without drug 
therapy, then uric acid lowering treatment (ULT) is indicated for an indefinite period to maintain a 
normal serum uric acid concentration, defined as less than 6 mg/dL (Khanna, 2012). Current options to 
treat excess uric acid include drugs that inhibit its enzymatic production, known as xanthine oxidase 
inhibitors (XOI). 
     The case study in this paper will focus on the XOI class in particular. Differentiating characteristics 
exist between the two marketed XOI, allopurinol and FBX. Allopurinol, approved by the FDA in 1966, is 
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an effective uric acid lowering drug, but must be used cautiously and at lower doses in patients with 
chronic kidney disease (CKD) due to the increased risk of severe allergic skin reactions. Such reactions 
are rare, but can become life-threatening. The dosing recommendations for gout patients with CKD 
remain unclear, leading many prescribers to underdose allopurinol in this group with resultant 
uncontrolled hyperuricemia. FBX was approved in 2009 and lacks the risk of allergic reactions that are 
associated with allopurinol. It is also safe to use at either marketed dosage strength (40 mg or 80 mg) in 
patients with CKD. This distinction from allopurinol allows more aggressive dosing of FBX in a critical 
subpopulation of gout patients so that serum uric acid may be reduced to the target concentration of 
less than 6 mg/dL .  
 
2. Study Rationale 
     Both allopurinol and FBX are considered first-line options for the treatment of hyperuricemia in gout 
(Khanna, 2012). Due to the shorter duration of time that FBX has been on the market, it costs about 10-
14 times as much as allopurinol. On the basis of a direct price comparison alone, one could conclude 
that allopurinol is more cost-effective than FBX. However, the overall costs associated with either 
therapy regarding the health care utilization of gout patients would need to be determined to assess 
their value relative to each other. Unfortunately, no published real-world data currently exist that 
compare the overall clinical and economic outcomes of XOI in gout patients. This is especially true with 
respect to other concurrent disease states and the accompanying treatment patterns with ULT. 
Enhanced knowledge of real world expenditures in gout patients may also help to further clarify the case 
to be made for the dominant value of FBX versus allopurinol. Data generated by analysis of databases 
that contain EHR and medical and prescription claims could be used to explore this issue. These data 
would be very useful to value-based health delivery systems, including managed care organizations and 
accountable care organizations (ACOs) and also could provide valuable insights for further innovations in 
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gout management. Therefore, the hypothesis of this study is that treatment with FBX will result in 
greater economic benefit than allopurinol as demonstrated by improved cost effectiveness and lower 
overall health care utilization. This hypothesis will be explored in CKD patients with gout, because they 
may experience the most benefit with respect to these outcomes from FBX as compared with 
allopurinol (Burns & Wortmann, 2011).  
 
     3.  Objectives 
a. The primary study objective is to determine the economic outcomes (using total direct cost) 
for patients with both gout and Stage 2 – Stage 4 CKD who are taking FBX compared with 
allopurinol. 
b. The secondary objective is to describe the incidence of gout flares (using diagnostic and 
procedural codes) for patients with both gout and Stage 2 – Stage 4 CKD who are taking FBX 
compared with allopurinol. 
 
     4. Methods  
4.1 Study Design 
     The study will be a retrospective cohort analysis using information extracted from MarketScan, a 
medical claims database. The two patient cohorts will both have gout and CKD and will be taking ULT as 
described later in this paper. Data extracted from MarketScan will include dates of service from January 
1, 2005 through December 31, 2012. 
 
          4.2 Study population  
     Enrollment in the study will be episode-based. Each patient may contribute multiple episodes to the 
analytic dataset provided all of the following criteria are met during each episode:  
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• Have at least one prescription for allopurinol or FBX between January 1, 2005 and December 31, 
2011; 
• Have a diagnosis of gout (as coded by ICD-9-CM 274.xx) on at least one inpatient claim or on two 
outpatient non-diagnostic claims prior to initiation of allopurinol or FBX; 
• Are continuously enrolled for at least 12 months prior and 12 months post allopurinol or FBX 
initiation; 
• Have both medical and pharmacy benefit plus complete data availability during both baseline 
and follow-up periods; 
• Have evidence of CKD, stages 2-4 as defined later, in the 12 months prior to index; 
• Are at least 18 years of age at the time of initiation of therapy with allopurinol or FBX; and 
• Have at least one laboratory value for serum uric acid in the 12-month period prior to initiation 
of therapy. 
     Patients will meet the CKD criteria if there is either an: 
• ICD 9 CM diagnosis code for CKD, stages 2-4, on at least one inpatient claim or at least two 
outpatient claims on different days between 30 and 365 days apart; or 
• CPT 4, HCPCS or ICD 9 procedure code on at least one medical claim, either inpatient or 
outpatient.  
     These claims are intended to capture data for patients that have a diagnosis or procedure coded for 
billing purposes for CKD with a reasonable expectation that this disease exists in such individuals. Since a 
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risk of misalignment of the coding for and true presence of CKD exists in any patient, the CKD status and 
stage will be corroborated with clinical laboratory data where available. 
     Patients will be followed within each treatment episode until disenrollment from MarketScan, end of 
the study period, discontinuation of either allopurinol or FBX or a prescription for the alternate agent. 
4.3 Propensity score matching 
     Propensity score matching will be used to minimize selection bias. The propensity model will 
characterize the probability that an individual will receive allopurinol or FBX on the basis of observed 
variables. Such variables in the propensity model may include age, type of health plan, geographic 
region, population density, the year the ULT was initiated, the number of gout flares during baseline, 
serum uric acid concentrations, the presence of specific clinical conditions, CKD stage, exposure to other 
gout therapies and/or exposure to other medication classes, e.g. cardiovascular medications. Patients 
treated with FBX subsequently will be matched with those treated with allopurinol with similar 
predicted probabilities. Matching will be performed for optimal statistical power and goodness-of-fit, 
ideally at a match ratio of 1 FBX:5 allopurinol patients. 
4.4 Data extraction and analysis 
     The primary economic outcome will be direct medical expenditure as measured during each 
treatment episode.  All direct medical expenditures will be captured regardless of fiscal obligation, 
including health plan insured amounts, coordination of benefits and patient co-payment, deductible, 
and co-insurance amounts. Expenditures will be stratified as gout-related or not gout-related and may 
be reported both in expenditures per month on therapy, per episode of therapy or per year as 
appropriate.  Expenditures will be further subdivided as follows: 
• Inpatient  
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• Outpatient 
• Office Visits 
• Emergency room 
• Pharmacy 
• Other 
 
     Means and standard deviations will be population-based. All costs will be standardized and reported 
in 2012 US dollars using the medical component of the Consumer Price Index.  Differences between all 
allopurinol and FBX cases will be considered statistically significant (p < 0.05 in a two-tailed test) if the 
95% CI does not include $0 for expenditures. 
     The primary clinical outcome will be the incidence and frequency of acute gout episodes or flares. For 
each clinical outcome, the number and proportion of patients experiencing a gout flare will be reported 
as will the incidence rate per unit of person time observed and time to event.  Kaplan–Meier survival 
curves will also be generated.  In addition, the mean (with standard deviation) number of acute flares 
per treatment episode will be reported.  
     The analysis will begin with simple statistics describing accrual into the study followed by the 
demographic and clinical characteristics of the sample overall, both pre- and post-propensity matching, 
stratified by exposure cohort. Subsequent tables will detail the frequency (counts and event rates) of 
acute gout flares in patients as well as first event descriptors, stratified again by exposure cohort. 
Additional tables will similarly summarize and report both all cause and gout specific direct medical 
expenditure and utilization statistics, also stratified by exposure cohort. 
     Basic analyses will include descriptive profiles of all independent and dependent variables. 
Categorical variables will be summarized in frequency tables. Continuous and other numeric variables 
will be summarized by presenting the number of observations, mean, standard deviation, and median. 
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Statistical tests of significance for differences in these distributions will be carried out. Chi-square tests 
will be used to assess the statistical significance of categorical variables; t-tests and ANOVA will be used 
for continuous variables. 
 
 Chapter 3: DISCUSSION 
1. Methods Analysis and Critique 
     Salient aspects of a claims database analysis include proper selection of the study design, the 
database, the patient cohorts, analysis plan, and reporting characteristics. The rationale and potential 
drawbacks of each aspect will be discussed in turn as illustrated by the case study. 
     The information captured in a claims database has by definition occurred in the past for specific 
health care encounters. Therefore, the retrospective design is most fitting, and the comparison of two 
or more cohorts of patients exposed to different interventions (or no intervention) strongly suggest that 
a retrospective cohort design is most appropriate. In the case study, the objective is to compare the 
overall direct medical costs of care between two similar groups of patients exposed to one of two 
treatments for gout. A prospective design would not be able to expeditiously answer this question, 
because it would require a multi-year duration, and would be influenced by factors that are unforeseen, 
such as the entry of additional drugs into the gout therapeutic area. Also, the uptake of a new agent 
such as FBX occurs no sooner than 12 months after FDA approval, so the data available for recipients of 
FBX in this study are likely limited to the 2010-12 time span.  
    The data source will be the Truven MarketScan® Commercial Claims and Encounters (Commercial) and 
the Medicare Databases including the MarketScan laboratory database.  The MarketScan® databases are 
the largest convenience sample available in a proprietary US claims database with 170 million unique 
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patients since 1995.  Nearly half of all US health plans, including many of the largest insurers, contribute 
to these databases.  In the most recent full data year, MarketScan claims databases contain data for 50 
million covered lives. Both claims databases include individuals covered under a variety of fee-for-
service, point of service, and capitated reimbursement schemes. Laboratory data are included from 
major national laboratory testing entities, such as LabCorp. The databases are HIPAA-compliant and as 
such are exempt from Institutional Review Board approval. Other available large commercial databases 
include the GE Healthcare database, which contains very robust electronic medical records and 
laboratory data, but are not integrated with prescription drug claims. The latter aspect was an 
overriding factor that precluded the inclusion of the GE product in the case study, because drug 
utilization data are essential for hypothesis testing. If prescription drug usage cannot be assessed, in this 
case study for either allopurinol or FBX, then its impact on outcomes is impossible to isolate. Even 
though initial fill and refill claims document that a point of care event has occurred, i.e., the dispensing 
of a prescription drug, this does not provide verification of patient adherence. This is a limitation of all 
claims database studies, because there is no way to verify that patients have actually taken the medicine 
they have received from the pharmacy other than contacting each individual in the database. Not only is 
this a violation of HIPAA policy, but it also is impractical, because there are millions of patients in a large 
database, and the answer provided would rely on recall of an event that may have occurred months or 
years in the past. The act of taking one’s medication as prescribed is known as adherence, and its 
assessment is particularly challenging using retrospective data. One method is to estimate the 
medication possession ratio (MPR) which is calculated as the days supply of drug dispensed for the 
evaluation period (typically at least 12 months) divided by the total number of days in the evaluation 
period (Andrade et al, 2006). An alternative to MPR is the daily consumption rate (DACON) which more 
crudely estimates adherence as the number of oral dosage units taken per day dispensed divided by the 
time. The DACON is more useful for medications that may be taken more than once daily. For the case 
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study, both allopurinol and FBX are indicated for once daily dosing; shortening the dosing interval more 
than that does not offer any therapeutic gain and may elevate the risk of adverse events or intolerance. 
     Another benefit of the MarketScan databases is the cross-section of claims represented in the 
sample. For example, the types of different commercial (non-government) insurance plans may vary 
greatly between patients, based on employer offerings, self-insured status, geography, medical history 
(in adults, prior to implementation of the PPACA in 2014), and income. Despite the acknowledged 
limitation that MarketScan does not contain claims from Medicaid, the Veterans Administration, many 
other commercial plans, and, certainly, uninsured individuals, a reasonably representative mix of 
insured patients is included from across the US. The last feature assists the researcher in overcoming 
variations in gout treatment by US geographic sector (Davis & Wreath, 2013). Without this component, 
there may be a treatment selection bias based on patient location, perhaps skewing the cost data in a 
positive direction. 
     Patient selection is quite possibly the part of OR studies requiring the most care and planning. If the 
cohorts are ill-defined, then incomplete, irrelevant, or unusable data may be collected. The case study 
requires that adults (age 18 years or greater) with gout be included since the two drugs are only 
indicated for that age group; allopurinol has FDA-approved indications other than gout, but FBX is 
approved only for the treatment of hyperuricemia in gout. The use of birthdates and ICD-9 diagnostic 
codes for gout will capture data for this cohort. The requirement of an additional comorbid condition, 
chronic kidney disease, further narrows the population of interest to those with a factor that 
complicates the management of gout in two ways. First, the dosing of allopurinol must be adjusted 
downward for impaired kidney function and, second, persistent elevations in uric acid are associated 
with progression of CKD. These patient characteristics form the crux of the hypothesis that FBX is 
especially well-suited to improve outcomes in this group, because it does not require dosage adjustment 
in CKD and possesses greater potency at lowering uric acid. Lastly, the National Kidney Foundation CKD 
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stages are used to define patients with gout who have comorbid CKD (NKF, 2002). The desired cohort 
would have stages 2, 3, and 4 disease whose severity is mild, moderate, or severe, respectively. Stage 1 
patients are excluded, because they have near normal kidney function and would not typically have any 
clinical findings or treatment associated with this degree of renal impairment. Also, Stage 5 patients are 
described as end-stage renal disease (ESRD) patients who require dialysis or kidney transplantation to 
survive. These patients would be excluded from analysis primarily because neither ULT drug has dosing 
recommendations for their use in this population.  
     Specification of claims that are episode-based is critical, because the expectation is that patients have 
an incident gout flare (as signified by a coded diagnosis of gout) followed within 12 months by a 
prescription claim for ULT. This specific sequence is necessary in order to establish that new users of ULT 
are included in the analysis. It is most advantageous to have new users of ULT, i.e., previously ULT-naïve, 
so that any carryover benefit or harm of previous ULT use is removed as a confounding variable. In 
addition, at least one serum uric acid concentration is required so that hyperuricemia is documented. 
Both allopurinol and FBX are indicated for the treatment of hyperuricemia in gout patients so both 
criteria must be present to align with this FDA-approved use. 
     The elements of the analysis plan are clearly developed and described a priori in accordance with 
good research practices for observational studies described previously. The use of propensity score 
matching, defined previously in this paper, will be employed in the case study, because it is the most 
reliable and valid method of mitigating potentially confounding patient characteristics. Multiple factors 
will be entered into the propensity score so as to reduce bias. Only direct medical costs will be included 
in the case study analysis, because indirect costs such as impact on lost income, reduced quality of life, 
and years of life lost, are not contained within a claims database. All of the various sectors of health care 
that potentially generate direct medical claims will be included as described in the methods section; this 
is so that the most complete accounting of costs can be assessed. The monetary value of total direct 
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costs will be compared using parametric statistical tests for continuous variables and the incidence of 
the primary clinical outcome (gout flares) will be compared for each therapy using a parametric test for 
proportions.  
     Reporting of the data results will follow the guidance of the STROBE document. This paper contains 
the elements required for compliance, including the title and abstract, introduction, and methods. The 
sole funding source is Takeda Pharmaceuticals International, Inc. The results and discussion will follow 
when available; but preliminary elements of the discussion appear in this paper, such as the limitations 
and generalizability of the data in general terms. 
     In spite of the carefully planned design and rigorously executed data analysis in the case study, 
disadvantages inherent in any retrospective claims database study may be present. Most concerning is 
the use of prescription claims as a surrogate for patient adherence to therapy. Evidence of initial and 
repeat filling of prescriptions is not an ideal measure of adherence, but given the current lack of patient-
centered data, it is the best available method at this time. A possible follow-on project of the case study 
would help address this deficiency through direct patient engagement to assess and confirm therapy 
adherence at the various points of care, such as the clinic, pharmacy, and community health centers. 
Another potential source of error is the misalignment of the coded diagnosis for gout and the true 
nature of the patient’s health condition. For example, gout may be mentioned in the differential 
diagnosis for joint pain upon presentation to a health care provider and coded as such. However, the 
ultimate diagnosis may not be gout. In the case study a documented serum uric acid concentration and 
prescription for ULT offers additional evidence to support the coded diagnosis. One method that confers 
the most confidence in the coded data was mentioned previously and involves taking a sample of 
patients and reviewing the medical record for progress notes to corroborate the presence of gout. This 
is known as validation, and is very resource-intensive to conduct for the entire cohort studied. 
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Therefore, in the case study, a sample of 50 patients will be analyzed for alignment of the gout code and 
medical record notes. 
 
2.  Future Steps 
     The case study constitutes the first phase of a research plan to assess and develop methods to 
improve the care and outcomes of patients with gout, especially those with comorbid CKD.  If the 
hypothesis is not rejected, then this would be the first analysis in the public domain to offer evidence of 
holistic economic benefit of one ULT versus another in a robust sample of gout patients. Specific 
patterns of medication use may be identified in the case study, such as when gout patients tend to stop 
taking ULT, when gout flares tend to recur and how often, and the types of health care expenditures 
observed with patients who experience worse gout outcomes. All of these data may serve as a platform 
for the development of patient engagement initiatives designed to improve adherence to gout therapy 
regimens. One method would be to implement on a pilot basis a patient outreach program for more 
active disease management through coordination of gout care between providers such as the hospital (if 
admitted for treatment of gout flare), primary care provider, consulting rheumatologist, and pharmacy. 
The data from the case study would assist in the identification of gout patients with CKD who are at the 
highest risk of nonadherence and resultant worse outcomes such as persistent elevations in uric acid, 
repeated gout flares, and increased likelihood of joint damage and reduced function and mobility. An 
ideal setting for this pilot project would be an accountable care organization (ACO) or other integrated 
health care delivery network (IDN) where a network of hospitals and providers are united by a shared 
responsibility for both clinical and financial outcomes. In the ACO model, the network is monetarily 
incentivized to improve the quality of care as evidenced by meeting outcome standards. Even though 
the gout disease state has not yet risen to the level of prominence where value-based payments are in 
place, it will be a matter of time before most conditions are paid for this way. The existence of US 
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guidelines for the management of gout specifies the use of particular ULT drugs to target a serum uric 
acid concentration of less than 6 mg/dL. Alignment of gout care and outcomes with these guidelines 
using innovative patient activation and adherence programs is one proposed step toward improvement 
in not just cost-effectiveness and quality, but also a better patient experience and engagement in their 
own care. These steps are intended to establish and reinforce the accountability of the health care 
system, but also that of the patient and his or her caregiver as stakeholders in the process of improving 
health outcomes. 
     In summary, OR is driving how currently available health care plans are assessed for quality, 
efficiency, and patient satisfaction (AHRQ, 2000). The grading of insurance coverage through newly 
established health care exchanges relies heavily on outcomes data, and this trend is expected to 
continue into the future as health care evolves into a consumer-centric rather than a provider-centric 
enterprise.  
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